Allergan, which is now part of AbbVie, announced that it will present new data advancing scientific understanding of an IOP-lowering treatment in glaucoma and evaluating an investigational treatment for presbyopia at American Academy of Ophthalmology (AAO) 2020 virtual meeting (November 13-15).
“It is imperative that we continue our mission to push forward research that addresses unmet treatment needs and bring innovative medicines that potentially improve the lives of people living with eye conditions and diseases such as presbyopia and glaucoma,” Michael Robinson, MD, vice president, global therapeutic area head, ophthalmology, AbbVie, said in a company news release. “This year at AAO 2020 Virtual, we’re proud to present new data for our IOP-lowering treatment Durysta, which delivers a much-needed option for glaucoma patients challenged by topical drops, and our investigational AGN-190584 for the treatment of presbyopia, which demonstrates potential to treat disruptive symptoms of presbyopia.”
Data presented at the meeting will include an analysis examining the safety and efficacy of Durysta and a second analysis of data from the phase 3 ARTEMIS studies that identify different characteristics of glaucoma patients who may respond after being treated with Durysta. These studies will add to the body of data for Durysta, an innovative treatment indicated to reduce IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
A real-world study that provides new insights on how people with glaucoma in the United Kingdom utilize available resources will also be available on the virtual meeting platform.
Additionally, a paper will be presented on a potential treatment for presbyopia from two phase 2b studies, which were used to identify the optimal concentration for the proprietary treatment formulation of investigational AGN-190584 used in future studies. AbbVie recently announced positive phase 3 results for AGN-190584 (pilocarpine 1.25%) ophthalmic solution.
Full text of all presentation abstracts can be accessed in the AAO 2020 Virtual meeting program. Those who have registered to attend AAO 2020 Virtual can view the data starting on Friday, November 13th.
Allergan will present:
- Two Phase 2b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia (Session: PA039, Paper – Recorded)
Presenting Author: Francis W Price Jr., M.D.
- Real-World Burden in Five Major United Kingdom Glaucoma Services (Session: PO207, Scientific Poster)
Presenting Author: Anthony P Khawaja, MBBS
- Predictive Factors for Long-Term IOP Lowering After Bimatoprost Implant 10-μg Administration in Phase 3 ARTEMIS Studies (Session: PO176, Scientific Poster)
Presenting Author: Albert S Khouri, M.D.
- Single Administration of Intracameral Bimatoprost Implant 10 μg: IOP Lowering and Safety (Session: PO181, Scientific Poster)
Presenting Author: Felipe A Medeiros, M.D.